$0.970500
0.011.06%
At Close: -
$0.949000
-0.02-2.22%
After Hours: 5:04 PM EDT
15 minutes delayed
Comments
Loading...
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Karyopharm Therapeutics (NASDAQ:KPTI) Stock, Analyst Ratings, Price Targets, Forecasts
Karyopharm Therapeutics Inc has a consensus price target of $8.64 based on the ratings of 11 analysts. The high is $27 issued by Morgan Stanley on October 12, 2021. The low is $3 issued by RBC Capital on November 3, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 28, 2024, June 3, 2024, and May 9, 2024, respectively. With an average price target of $7.67 between HC Wainwright & Co., there's an implied 707.87% upside for Karyopharm Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Piper Sandler
RBC Capital
Morgan Stanley
Wedbush
1calculated from analyst ratings
Analyst Ratings for Karyopharm Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 637.62% | HC Wainwright & Co. | Edward White | $8 → $7 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 742.99% | HC Wainwright & Co. | Edward White | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 742.99% | HC Wainwright & Co. | Edward White | → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 742.99% | HC Wainwright & Co. | Edward White | $10 → $8 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 426.87% | Piper Sandler | Christopher Raymond | $7 → $5 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 216.12% | RBC Capital | Brian Abrahams | $4 → $3 | Maintains | Outperform | Get Alert |
| 08/07/2023 | Buy Now | 321.5% | Morgan Stanley | Michael Ulz | $5 → $4 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | 637.62% | Piper Sandler | Christopher Raymond | $8 → $7 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | 321.5% | RBC Capital | Brian Abrahams | $5 → $4 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | 953.74% | HC Wainwright & Co. | Edward White | → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | 321.5% | Wedbush | David Nierengarten | $7 → $4 | Maintains | Neutral | Get Alert |
| 07/26/2023 | Buy Now | 953.74% | HC Wainwright & Co. | Edward White | → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/18/2023 | Buy Now | 953.74% | HC Wainwright & Co. | Edward White | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 426.87% | RBC Capital | Brian Abrahams | $6 → $6 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 953.74% | HC Wainwright & Co. | Edward White | $16 → $10 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 953.74% | Baird | Mitch Collett | $14 → $10 | Maintains | Outperform | Get Alert |
| 04/19/2023 | Buy Now | 1585.99% | HC Wainwright & Co. | Edward White | → $16 | Reiterates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | 1585.99% | HC Wainwright & Co. | Edward White | → $16 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | 1585.99% | HC Wainwright & Co. | Edward White | → $16 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 426.87% | Morgan Stanley | Michael Ulz | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 01/19/2023 | Buy Now | 742.99% | Piper Sandler | Christopher Raymond | → $8 | Initiates | → Overweight | Get Alert |
| 01/10/2023 | Buy Now | 1585.99% | HC Wainwright & Co. | Edward White | $18 → $16 | Maintains | Buy | Get Alert |
| 01/10/2023 | Buy Now | 426.87% | SVB Leerink | Jonathan Chang | $6 → $5 | Maintains | Market Perform | Get Alert |
| 11/04/2022 | Buy Now | 953.74% | RBC Capital | Brian Abrahams | $7 → $10 | Upgrade | Sector Perform → Outperform | Get Alert |
| 11/04/2022 | Buy Now | 532.24% | SVB Leerink | Jonathan Chang | $5 → $6 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 637.62% | Morgan Stanley | Michael Ulz | $10 → $7 | Maintains | Equal-Weight | Get Alert |
| 08/05/2022 | Buy Now | 1796.73% | HC Wainwright & Co. | Edward White | $21 → $18 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | 1375.24% | Baird | Colleen Kusy | $17 → $14 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | 742.99% | Barclays | Peter Lawson | $14 → $8 | Maintains | Overweight | Get Alert |
| 05/05/2022 | Buy Now | 426.87% | SVB Leerink | Jonathan Chang | $6 → $5 | Maintains | Market Perform | Get Alert |
| 03/18/2022 | Buy Now | 2218.23% | HC Wainwright & Co. | Edward White | $23 → $22 | Maintains | Buy | Get Alert |
| 03/08/2022 | Buy Now | 742.99% | RBC Capital | Brian Abrahams | $12 → $8 | Maintains | Sector Perform | Get Alert |
| 03/02/2022 | Buy Now | 532.24% | SVB Leerink | Jonathan Chang | $8 → $6 | Maintains | Market Perform | Get Alert |
| 02/09/2022 | Buy Now | 742.99% | JP Morgan | Eric Joseph | → $8 | Upgrade | Underweight → Neutral | Get Alert |
| 01/10/2022 | Buy Now | 742.99% | SVB Leerink | Jonathan Chang | $6 → $8 | Maintains | Market Perform | Get Alert |
| 12/09/2021 | Buy Now | 848.37% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 11/19/2021 | Buy Now | 953.74% | Morgan Stanley | Michael Ulz | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 10/12/2021 | Buy Now | 2745.1% | Morgan Stanley | David Lebowitz | — | Maintains | Overweight | Get Alert |
| 08/06/2021 | Buy Now | 2639.73% | HC Wainwright & Co. | Edward White | — | Maintains | Buy | Get Alert |
| 08/06/2021 | Buy Now | 532.24% | SVB Leerink | Jonathan Chang | — | Downgrade | Outperform → Market Perform | Get Alert |
| 08/06/2021 | Buy Now | 742.99% | RBC Capital | Brian Abrahams | — | Downgrade | Outperform → Sector Perform | Get Alert |
| 08/06/2021 | Buy Now | — | JP Morgan | Eric Joseph | — | Downgrade | Overweight → Underweight | Get Alert |
FAQ
What is the target price for Karyopharm Therapeutics (KPTI) stock?
The latest price target for Karyopharm Therapeutics (NASDAQ:KPTI) was reported by HC Wainwright & Co. on June 28, 2024. The analyst firm set a price target for $7.00 expecting KPTI to rise to within 12 months (a possible 637.62% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Karyopharm Therapeutics (KPTI)?
The latest analyst rating for Karyopharm Therapeutics (NASDAQ:KPTI) was provided by HC Wainwright & Co., and Karyopharm Therapeutics maintained their buy rating.
When was the last upgrade for Karyopharm Therapeutics (KPTI)?
The last upgrade for Karyopharm Therapeutics Inc happened on November 4, 2022 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for Karyopharm Therapeutics Inc.
When was the last downgrade for Karyopharm Therapeutics (KPTI)?
The last downgrade for Karyopharm Therapeutics Inc happened on November 19, 2021 when Morgan Stanley changed their price target from $27 to $10 for Karyopharm Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Karyopharm Therapeutics (KPTI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Karyopharm Therapeutics (KPTI) correct?
While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a maintained with a price target of $8.00 to $7.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $0.95, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.